Trial Profile
Comparative Efficacy of Lixisenatide and Liraglutide on glucose variability and safety in CGM in Type 2 Diabetes with long-acting insulin
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2018
Price :
$35
*
At a glance
- Drugs Liraglutide (Primary) ; Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 09 Jan 2018 Status changed from recruiting to discontinued.
- 26 May 2016 New trial record